The influence of tumor volume on the risk of distant metastases in head and neck squamous cell carcinomas.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
09 2023
Historique:
received: 16 03 2023
revised: 19 06 2023
accepted: 21 06 2023
medline: 21 8 2023
pubmed: 30 6 2023
entrez: 29 6 2023
Statut: ppublish

Résumé

Distant metastases (DM) in head and neck squamous cell carcinomas (HNSCC) are in most circumstances non-curable. The TNM staging system is insufficient to predict the risk of DM. This study investigates if the DM risk can be predicted using a multivariate model including pre-treatment total tumor volume for both p16-positive oropharyngeal squamous cell carcinoma (OPSCC) and all other sites (other HNSCC). The study includes patients with localized pharyngeal and laryngeal squamous cell carcinomas treated with primary radiotherapy from 2008-2017 from three head and neck cancer centers. Patients were identified in the Danish Head and Neck Cancer (DAHANCA) database. Total (nodal and primary) tumor volume (Gross Tumor Volume, GTV) was extracted from local treatment planning systems. The GTV was grouped by volume (cm The study includes 2,865 patients, of which 321 (11 %) had DM post-treatment. The risk of DM was assessed in a multivariate model based on 2,751 patients (p16-positive OPSCC: 1,032; and other HNSCC: 1,719). There was a significant association between GTV and the risk of DM, and in tumor volumes ≥ 50 cm Tumor volume is an independent risk factor for DM. The addition of total tumor volume to a predictive model is important to identify subgroups of HNSCC patients at high risk of DM.

Sections du résumé

BACKGROUND AND PURPOSE
Distant metastases (DM) in head and neck squamous cell carcinomas (HNSCC) are in most circumstances non-curable. The TNM staging system is insufficient to predict the risk of DM. This study investigates if the DM risk can be predicted using a multivariate model including pre-treatment total tumor volume for both p16-positive oropharyngeal squamous cell carcinoma (OPSCC) and all other sites (other HNSCC).
MATERIALS AND METHODS
The study includes patients with localized pharyngeal and laryngeal squamous cell carcinomas treated with primary radiotherapy from 2008-2017 from three head and neck cancer centers. Patients were identified in the Danish Head and Neck Cancer (DAHANCA) database. Total (nodal and primary) tumor volume (Gross Tumor Volume, GTV) was extracted from local treatment planning systems. The GTV was grouped by volume (cm
RESULTS
The study includes 2,865 patients, of which 321 (11 %) had DM post-treatment. The risk of DM was assessed in a multivariate model based on 2,751 patients (p16-positive OPSCC: 1,032; and other HNSCC: 1,719). There was a significant association between GTV and the risk of DM, and in tumor volumes ≥ 50 cm
CONCLUSION
Tumor volume is an independent risk factor for DM. The addition of total tumor volume to a predictive model is important to identify subgroups of HNSCC patients at high risk of DM.

Identifiants

pubmed: 37385382
pii: S0167-8140(23)00309-2
doi: 10.1016/j.radonc.2023.109771
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109771

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Julie Kjems (J)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Electronic address: julie.kjems@regionh.dk.

Katrin Elisabet Håkansson (K)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Electronic address: katrin.elisabet.haakansson@regionh.dk.

Claus Andrup Kristensen (C)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Electronic address: Claus.Andrup.Kristensen@regionh.dk.

Jesper Grau Eriksen (J)

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: jesper@oncology.au.dk.

Morten Horsholt Kristensen (M)

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: mortenhorsholt@oncology.au.dk.

Anne Ivalu Sander Holm (A)

Department of Oncology, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: annivaho@rm.dk.

Jens Overgaard (J)

Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus 8200, Denmark. Electronic address: jens@oncology.au.dk.

Christian Rønn Hansen (C)

Department of Oncology, Odense University Hospital, Odense 5000, Denmark; Laboratory of Radiation Physics, Odense University Hospital, Odense 5000, Denmark; Department of Clinical Research, University of Southern Denmark, Odense 5000, Denmark. Electronic address: christian.roenn@rsyd.dk.

Ruta Zukauskaite (R)

Department of Oncology, Odense University Hospital, Odense 5000, Denmark. Electronic address: Ruta.Zukauskaite@rsyd.dk.

Jørgen Johansen (J)

Department of Oncology, Odense University Hospital, Odense 5000, Denmark. Electronic address: j.johansen@dadlnet.dk.

Ivan Richter Vogelius (I)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Electronic address: ivan.richter.vogelius@regionh.dk.

Jeppe Friborg (J)

Department of Oncology, Copenhagen University Hospital - Rigshospitalet, Copenhagen 2100, Denmark. Electronic address: jeppe.friborg@regionh.dk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH